S&P 500
(1.03%) 5 180.74 points
Dow Jones
(0.46%) 38 852 points
Nasdaq
(1.19%) 16 349 points
Oil
(0.46%) $78.84
Gas
(0.36%) $2.20
Gold
(0.12%) $2 334.10
Silver
(0.28%) $27.69
Platinum
(0.27%) $967.50
USD/EUR
(-0.05%) $0.928
USD/NOK
(-0.44%) $10.83
USD/GBP
(-0.13%) $0.796
USD/RUB
(-0.12%) $91.35

Actualizaciones en tiempo real para Oxurion NV [OXUR.BR]

Bolsa: EURONEXT Industria: Biotechnology
Última actualización6 may 2024 @ 11:35

0.00% 0.000200

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 11:35):

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction...

Stats
Volumen de hoy 129.10M
Volumen promedio 104.90M
Capitalización de mercado 1.48M
EPS €0 ( 2024-04-05 )
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E 0
ATR14 €0 (0.00%)

Oxurion NV Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oxurion NV Finanzas

Annual 2023
Ingresos: €263 000
Beneficio Bruto: €104 000 (39.54 %)
EPS: €-0.0115
FY 2023
Ingresos: €263 000
Beneficio Bruto: €104 000 (39.54 %)
EPS: €-0.0115
FY 2022
Ingresos: €595 000
Beneficio Bruto: €-271 000 (-45.55 %)
EPS: €-0.370
FY 2021
Ingresos: €1.13M
Beneficio Bruto: €516 000 (45.74 %)
EPS: €-0.928

Financial Reports:

No articles found.

Oxurion NV

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico